Topics

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

10:55 EDT 15 Aug 2019 | SCRIP

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage...

      

Related Stories

 

Original Article: Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

NEXT ARTICLE

More From BioPortfolio on "Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease"

Quick Search